Biotech Values

[DewDiligence]

I think there’s a 35-40% chance of an approvable letter requiring the outcome of 9002b, which would be devastating for the share price given the now-lofty valuation, the 2-3 year wait for the 9902b data, and the possibility that 9902b could fail. I do not plan to buy on the come; if the drug is approved, I’ll evaluate the merits of buying based on the valuation at that time.

You might want to look at the results of survey #87 on this board (http://www.investorshub.com/boards/board_survey_results.asp?board_id=1418&Survey_Num=87 ). Approximately one third of the voters are more bearish than I am and think an approvable letter requiring 9902b is not just possible but the most likely outcome. By and large, the people who vote in surveys on this board are not dummies, so I would not dismiss their views lightly.

Good luck whatever you do. Does your question imply that you are selling the bank CDs?